

HEALTH AND MEDICINE

Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing

Natascha Sommer¹, Nasim Alebrahimdehordi¹, Oleg Pak¹, Fenja Knoepp¹, Ievgen Strielkov¹, Susan Scheibe¹, Eric Dufour², Ana Andjelković², Akylbek Sydykov¹, Alireza Saraji¹, Aleksandar Petrovic¹, Karin Quanz¹, Matthias Hecker¹, Manish Kumar¹, Joel Wahl³, Simone Kraut¹, Werner Seeger¹, Ralph T. Schermuly¹, Hossein A. Ghofrani^{1,4}, Kerstin Ramser³, Thomas Braun⁵, Howard T. Jacobs², Norbert Weissmann^{1*}, Marten Szibor^{2*†}

Copyright © 2020
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim to
original U.S. Government
Works. Distributed
under a Creative
Commons Attribution
NonCommercial
License 4.0 (CC BY-NC).

Mitochondria play an important role in sensing both acute and chronic hypoxia in the pulmonary vasculature, but their primary oxygen-sensing mechanism and contribution to stabilization of the hypoxia-inducible factor (HIF) remains elusive. Alteration of the mitochondrial electron flux and increased superoxide release from complex III has been proposed as an essential trigger for hypoxic pulmonary vasoconstriction (HPV). We used mice expressing a tunicate alternative oxidase, AOX, which maintains electron flux when respiratory complexes III and/or IV are inhibited. Respiratory restoration by AOX prevented acute HPV and hypoxic responses of pulmonary arterial smooth muscle cells (PASMC), acute hypoxia-induced redox changes of NADH and cytochrome c, and superoxide production. In contrast, AOX did not affect the development of chronic hypoxia-induced pulmonary hypertension and HIF-1 α stabilization. These results indicate that distal inhibition of the mitochondrial electron transport chain in PASMC is an essential initial step for acute but not chronic oxygen sensing.

INTRODUCTION

Hypoxic pulmonary vasoconstriction (HPV) is a vital response mechanism that diverts pulmonary blood flow away from poorly ventilated to well-ventilated lung alveoli, thereby optimizing arterial oxygenation under conditions of local alveolar hypoxia (1, 2). Disturbed or inappropriate HPV may cause life-threatening oxygen deprivation, for instance during anesthesia, pneumonia, adult respiratory distress syndrome, septic events, or liver failure. It also contributes to the development of high-altitude pulmonary edema. Under global alveolar hypoxia, HPV can also cause an increase in pulmonary vascular pressure. This occurs naturally in the hypoxic lungs of the unborn fetus, and inappropriate continuation of HPV after birth causes persistent pulmonary hypertension (PH) of the newborn, which is associated with significant mortality and morbidity (3). HPV also contributes to the development of PH caused by chronic hypoxia-induced pulmonary vascular remodeling, which can eventually lead to right heart failure (4).

Recently, we provided evidence that acute HPV may be regulated by a central oxygen sensor within the mitochondrial respiratory chain, which depends on the presence of the mitochondrial complex IV [cIV; cytochrome c (Cyt c) oxidase] subunit 4 isoform 2 (Cox4i2) (5). We were able to demonstrate that acute hypoxia induces Cox4i2-dependent mitochondrial hyperpolarization, leading to increased mitochondrial superoxide release from the respiratory com-

plex III (cIII; ubiquinol:Cyt c oxidoreductase) and/or complex I [cI; reduced form of nicotinamide adenine dinucleotide (NADH):ubiquinone oxidoreductase] with subsequent inhibition of cellular potassium channels (K_V), cellular membrane depolarization, and activation of voltage-gated calcium channels, resulting in intracellular calcium increase and HPV. Similarly, we found that chronic hypoxia results in mitochondrial membrane hyperpolarization (6) and K_V channel inhibition (7), leading to a proliferative and antiapoptotic phenotype of pulmonary arterial smooth muscle cells (PASMC). However, the underlying mechanism for these alterations remains elusive. In particular, it remains unclear whether inhibition of mitochondrial respiration by oxygen deprivation at cIV could act as the actual trigger for HPV under acute hypoxia, as HPV is caused already by mild hypoxia at oxygen levels at which cIV oxygen affinity should overcome inhibitory consequences. Moreover, the downstream signaling consequences are still under debate and decreased reactive oxygen species (ROS) release from cI (8) during acute hypoxia contrasts to the concept of increased ROS from cIII being the major cause (9). Conversely, there is broad consensus that chronic hypoxia inhibits mitochondrial respiration regulated by hypoxia-inducible factor 1 α (HIF-1 α)-dependent gene expression. HIF-1 α stabilization, in turn, has been suggested to depend on mitochondrial ROS release. We, thus, investigated (i) whether HPV and chronic hypoxia-induced PH and HIF-1 α stabilization are prompted by hypoxia-induced inhibition of mitochondrial respiration, (ii) the mechanisms of downstream signaling of the mitochondrial respiratory chain, and (iii) whether partial restoration of mitochondrial respiration by expression of alternative oxidase (AOX) could prevent HPV and hypoxia-induced PH.

To this end, we made use of a mouse model ubiquitously expressing *Ciona intestinalis* AOX (10), hereafter referred to as AOX mouse. Many organisms, including plants and some metazoans, but not insects and mammals, have AOX, which branches the mitochondrial respiratory chain when electron flux through cIII and cIV is impaired and the quinone pool is highly reduced (11, 12). Under such conditions, AOX accepts electrons from ubiquinol and directly reduces

¹Excellence Cluster Cardio-Pulmonary Institute (CPI), University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus-Liebig-University, Giessen, D-35392 Giessen, Germany. ²Faculty of Medicine and Health Technology, Tampere University, FI-33014 Tampere, Finland. ³Department of Engineering Sciences and Mathematics, Luleå University of Technology, SE-97187 Luleå, Sweden. ⁴Department of Medicine, Imperial College London, Du Cane Road, Hammersmith Campus, London W12 0NN, UK. ⁵Department I, Cardiac Development and Remodelling, Max Planck Institute for Heart and Lung Research, D-61231 Bad Nauheim, Germany.

*Corresponding author. Email: marten.szibor@tuni.fi (M.S.); norbert.weissmann@innere.med.uni-giessen.de (N.W.)

†Present address: Department of Cardiothoracic Surgery, Jena University Hospital, D-07747 Jena, Germany.

oxygen to water in a thermogenic reaction. AOX thus prevents overreduction of the mitochondrial quinone pool and the resulting excess ROS production and maintains the activity of the Krebs cycle. Despite its enzymatic function, AOX expression alone does not disturb normal mouse physiology (10, 13). However, it is able to correct pathological states associated with respiratory inhibition, notably those affecting cIII and/or cIV (10, 13–16). This makes AOX a valuable tool to study the involvement of mitochondria and their hierarchy in physiological and pathophysiological processes affecting health and disease (17–19).

RESULTS

AOX is expressed in the pulmonary vasculature and inhibits HPV under acute hypoxia

We first verified widespread AOX expression in the lung, including the vasculature and airways (Fig. 1A), and then tested the effects of AOX on cyanide- (fig. S1) and hypoxia-induced vasoconstriction (Fig. 1B). Vasoconstriction was quantified as the increase in pulmonary




Fig. 1. Acute HPV is absent in AOX-expressing isolated murine lungs. (A) AOX protein expression detected as brownish color in bronchial walls (*) and pulmonary arteries (arrows). (B) PAP response of isolated, buffer-perfused WT and AOX murine lungs ventilated with 1% O₂ for time as indicated. Data are shown as means \pm SEM of $n = 9$ experiments. Gray area indicates significant difference with $P < 0.05$ tested by multiple t tests. (C) PAP response to hypoxic (HOX; 1% O₂) challenge with and without AOX inhibitor nPG applied 5 min before sequential HOX. Data are shown as means \pm SEM of $n = 4$ experiments. * $P < 0.05$, *** $P < 0.001$ for comparison as indicated, analyzed by two-way analysis of variance (ANOVA) and Sidak's multiple comparisons test. (D) PAP response to pulmonary artery infusion of the thromboxane mimetic U46619. Data are shown as means \pm SEM of $n = 6$ experiments. (E) Kfc after 90 min of ischemia. Data are shown as means \pm SEM of $n = 3$ experiments. (F) Lung weight gain (retention) during reperfusion after 90 min of ischemia. Data are shown as means \pm SEM of $n = 3$ experiments.

arterial pressure (Δ PAP) in isolated, ventilated lungs perfused with buffer at constant flow. In wild-type (WT) lungs, Δ PAP reached a maximum value after 10 min of hypoxic ventilation (acute HPV), transiently decreasing before rising again under prolonged hypoxia of up to 3 hours (sustained HPV) (Fig. 1B). AOX-expressing lungs showed inhibition of HPV under acute hypoxia (Fig. 1B) and a diminished PAP response in the presence of cyanide (fig. S1). HPV inhibition by AOX was confirmed using the AOX-specific inhibitor *n*-propyl gallate (nPG). The presence of nPG during 10 min of hypoxic ventilation abrogated the AOX effect and restored HPV (Fig. 1C). To verify that the effect of AOX was not due to nonspecific lung damage and/or impaired calcium signaling, we stimulated isolated lungs with the hypoxia-independent vasoconstrictor U46619, a thromboxane mimetic. WT and AOX lungs responded similarly to U46619 (Fig. 1D), with an increase in PAP indicating intact pulmonary vasculature physiology, showing the AOX effect to be specific to HPV and, thus, oxygen-dependent vasoconstriction.

Moreover, there was no difference between isolated WT and AOX-overexpressing lungs with regard to postischemic endothelial damage during ischemia-reperfusion, measured as the increase in capillary filtration rate (Kfc; Fig. 1E) and gain of lung weight (Fig. 1F). These results support the conclusion that AOX expression in murine lungs specifically inhibited the response of the pulmonary vasculature to acute and sustained hypoxia and, notably, implicate different underlying mechanisms in ischemia-reperfusion injury.

AOX decreases hypoxia-induced cellular membrane depolarization in PASMC

We next investigated the hypoxia response in isolated PASMC. Since cellular membrane depolarization is an essential step in HPV signaling, upstream of cytoplasmic calcium increase but downstream of superoxide release, we measured cellular membrane potential by patch clamp analysis. In WT PASMC, cellular membrane potential was increased upon exposure to hypoxia (Fig. 2, A and C). By contrast, the hypoxic response in AOX PASMC was blunted (Fig. 2, B and D), with the membrane potential reaching a lower plateau level than in WT (Fig. 2E). AOX inhibition by nPG renormalized membrane depolarization (Fig. 2, B, D, and E), while the basal membrane potential did not differ between WT and AOX PASMC (Fig. 2, C and D). Again, this indicates that AOX, by accepting electrons from ubiquinol, specifically interferes with the hypoxic signal originating from mitochondria, leaving general cellular physiology unaffected.

To test this assumption in a more physiological context, we measured hypoxia-induced vasoconstriction of pulmonary arterial vessels, which was again prevented by AOX (Fig. 2F). However, vasoconstriction was restored in isolated vessels expressing AOX when perfused with potassium chloride (Fig. 2, F and G). Moreover, we observed that addition of potassium chloride to the perfusate in isolated AOX lungs also restored HPV (Fig. 2H). This indicates that mitochondria, and specifically the electron flux through the respiratory chain, lie upstream of potassium channel inhibition in the hierarchy of acute HPV signaling, and reveals that other minor hypoxia-dependent processes must contribute to reaching the threshold of depolarization necessary to trigger HPV.

AOX inhibits hypoxia-induced mitochondrial superoxide release and membrane hyperpolarization in PASMC

Since a hallmark of impaired electron flux through the respiratory chain is the production of ROS and reactive nitrogen species (RNS),




Fig. 2. Hypoxia-induced cellular membrane depolarization is decreased in AOX-expressing PASM. (A and B) Representative traces of patch clamp measurements to determine cellular membrane potential (MP) during acute HOX (1% O₂) in mouse WT (A) and AOX (B) PASM. Gray traces depict oxygen concentration in %; blue (WT) and red (AOX) traces indicate MP in millivolts. Addition of AOX inhibitor nPG as indicated. Cellular MP in mouse WT (C) and AOX (D) PASM during normoxia (NOX) and acute HOX or acute HOX plus nPG. (E) Change of cellular MP compared with NOX in the absence and presence of nPG as indicated. Data of (C) to (E) shown as means ± SEM of *n* = 6 experiments. Horizontal bars indicate significant difference with *P* < 0.05 analyzed by repeated-measures one-way ANOVA and Tukey's multiple comparisons test. (F) Vasoconstriction of isolated pulmonary arteries during superfusion with hypoxic (1% O₂) or normoxic KCl-free buffer shown as % of response to 80 mM KCl. Data are shown as means ± SEM of *n* = 8 experiments. **P* < 0.05 WT NOX versus WT HOX; #*P* < 0.05 WT HOX versus AOX HOX analyzed by two-way ANOVA and Tukey's multiple comparisons test. (G) Vasoconstriction as in (F) but in the presence of ~20 mM KCl. Data are shown as means ± SEM of *n* = 8 experiments. **P* < 0.05 WT NOX versus WT HOX; #*P* < 0.05 WT NOX versus AOX HOX analyzed by two-way ANOVA and Tukey's multiple comparisons test. (H) PAP response of isolated WT and AOX lungs during HOX (10% O₂) ventilation before and after infusion of 20 mM KCl. Data are shown as means ± SEM of *n* = 3 experiments. Horizontal bars indicated significant difference with *P* < 0.05 analyzed by two-way ANOVA and Sidak's multiple comparisons test.

we tested whether ROS/RNS are the mitochondrial signals that trigger HPV. We measured ROS/RNS release in hypoxia-exposed snap-frozen mouse PASM using the spin probe CMH (1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine) with electron spin resonance (ESR) spectroscopy (Fig. 3A). To determine the proportion of superoxide within the total ROS/RNS load, we incubated parallel samples with polyethylene glycol-conjugated superoxide dismutase (pSOD) (Fig. 3, A and B). Superoxide levels increased under hypoxic conditions in WT but not in AOX PASM. To validate this finding, we expressed either native AOX or a catalytically inactive mutant AOX (20) in WT mouse PASM. Only the inactive mutant AOX showed a hypoxia-dependent increase in superoxide

(Fig. 3C). To investigate the mechanism behind increased superoxide production, we measured the mitochondrial membrane potential ($\Delta\psi$), which was increased in WT but not in AOX PASM during superfusion with hypoxic medium (Fig. 3, D and E). We also assayed the oxygen dependence of mitochondrial respiration, in this case using transfected rat PASM (rPASM) to obtain sufficient material. rPASM transfected with an AOX expression plasmid or with empty vector both showed decreased respiration under oxygen deprivation. However, at low oxygen concentrations, AOX-expressing rPASM had slightly, but significantly, higher oxygen consumption than the control (Fig. 3F). These data confirm that AOX is catalytically engaged during acute hypoxic inhibition of the respiratory chain,




Fig. 3. AOX inhibits hypoxia-induced superoxide release and mitochondrial membrane hyperpolarization in PASM and affects the redox state of mitochondrial biomarkers. (A) Representative ESR spectra from mouse WT and AOX PASM using the probe CMH and pSOD for control. (B) Superoxide production in mouse WT and AOX PASM during exposure to normoxia (NOX) and hypoxia (HOX, 1% O₂) for 5 min. A.U., arbitrary units. Data are shown as means ± SEM of *n* = 4 experiments. The horizontal bar indicates significant difference with *P* < 0.05 analyzed by two-way ANOVA and Sidak's multiple comparisons test. (C) Superoxide production in WT mouse PASM transfected with plasmids encoding native Ciona AOX or a catalytically inactive mutant AOX exposed to NOX and HOX. Data are shown as means ± SEM of *n* = 12 experiments. The horizontal bar indicates significant difference with *P* < 0.05 analyzed by two-way ANOVA and Sidak's multiple comparisons test. No significant differences were detected between the genotypes. Data in (B) and (C) are depicted as the portion of CMH signal inhibited by pSOD. (D) Representative mouse WT and AOX PASM stained with JC-1 under normoxia and hypoxia (1% O₂) as indicated. (E) Mitochondrial MP (Mito MP) determined as JC-1 red/green ratio under acute HOX as indicated. Data are shown as means ± SEM of *n* = 10 (WT) and *n* = 12 (AOX) experiments. Gray area depicts significant difference with *P* < 0.05 analyzed by two-way ANOVA and uncorrected Fisher's least significant difference (LSD). (F) Oxygen-dependent respiratory rate of 100,000 to 300,000 intact rPASM per experiment transfected with an empty vector or AOX encoding plasmid. Data are shown as means ± SEM in % of rate at normoxia (max) with *P* < 0.0001 indicating significant difference between WT and AOX analyzed by paired *t* test. (G) Normalized fluorescence-corrected Savitzky-Golay reconstructed Raman spectra taken from WT (*n* = 4) and AOX (*n* = 6) PASM before (black line = NOX) and after (gray line) exposure to acute hypoxia (HOX, 5% O₂). Background spectrum from microfluidic system and buffer solution is shown as dashed line (*n* = 25). Differences between NOX and HOX are highlighted with a difference spectrum for each corresponding sample type (WT, blue; AOX, red). Peak locations for mitochondrial biomarkers NAD⁺ (3: 1033 cm⁻¹), NADH (2: 1000 cm⁻¹), ubiquinol (QH₂; 5: 1167 cm⁻¹), and cytochrome b (Cyt b; 7: 1337 cm⁻¹) as well as peaks associated with reduced (1: 750 cm⁻¹; 4: 1127 cm⁻¹; 6: 1313 cm⁻¹; 9: 1505 cm⁻¹) and oxidized forms of Cyt c (8: 1369 cm⁻¹; 10: 1638 cm⁻¹) are shown as vertical dashed lines. (H) Raman intensity for individual biomarkers are shown as means ± SEM of *n* ≥ 3 experiments. ns, not significant. **P* < 0.05; ***P* < 0.01; ****P* < 0.001 analyzed by two-way ANOVA and uncorrected Fisher's LSD.

thereby affecting, besides ROS production, the mitochondrial redox state and accumulation of Krebs cycle intermediates.

AOX affects the mitochondrial redox state

In respiring mitochondria, the redox state of the individual chain complexes is highly dynamic and depends particularly on oxygen supply. Accordingly, hypoxic inhibition at cIV should impair electron flux in WT PASM, thereby reducing the individual mitochondrial complexes and ultimately resulting in an increased cellular NADH/NAD⁺ ratio. Since AOX branches the mitochondrial chain when electron flux through cIII and cIV is impaired (14), we hypothesized that both the redox state of mitochondrial complexes downstream of AOX and the NADH/NAD⁺ ratio would be unaffected by hypoxic challenge in AOX PASM. To test this hypothesis, we performed Raman spectroscopy, which allows the redox state of individual mitochondrial complexes and NADH/NAD⁺ ratios to be simultaneously studied in single living PASM (21–25). As expected, acute hypoxia shifted NADH, ubiquinol (QH₂), and Cyt c in WT PASM toward a more reduced state (Fig. 3, G and H, and fig. S2, A and B). The redox state of cytochrome b (Cyt b) was unaltered, which is

indicative for an electron leak at cIII. In accordance with our hypothesis, no change in redox state at cIII (Cyt b) and cIV (Cyt c) was observed in AOX PASM (Fig. 3H and fig. S2B), consistent with a bypass of electrons from reduced ubiquinol to AOX. Furthermore, NAD⁺, but not NADH levels, increased upon hypoxia (Fig. 3H). These findings further support the concept of AOX being catalytically engaged in acute hypoxic inhibition and suggest that NADH is the respective electron donor for mitochondrial respiration through AOX.

AOX does not affect adaptation processes upon chronic hypoxia

Notably, mitochondrial impairment has also been identified as an underlying mechanism for chronic hypoxia-induced PH (26), a life-threatening disease occurring, for example, at high altitude. To test whether AOX expression can also prevent the adverse effects of generalized chronic hypoxia, we exposed WT and AOX mice to 4 weeks of hypoxia (10% O₂). In contrast to expectations, both WT and AOX mice developed PH to a similar degree, with similar alterations in right ventricular systolic pressure (Fig. 4A), right ventricular hypertrophy (Fulton index; Fig. 4B), cardiac output (Fig. 4C), and




Fig. 4. Adaptation processes upon chronic hypoxia in WT and AOX transgenic mice. (A) Right ventricular systolic pressure (RVSP) after normoxia (NOX) or hypoxia (HOX, 10% O₂) for 28 days. Data are shown as means ± SEM of $n \geq 9$ experiments. Horizontal bars indicate significant difference with $P < 0.05$ analyzed by two-way ANOVA and Tukey's multiple comparisons test. (B) Ratios of right ventricle (RV) and left ventricle (LV) plus septum (S) (Fulton index). Data are shown as means ± SEM of $n = 10$ experiments. Horizontal bars indicate significant difference with $P < 0.05$ analyzed by two-way ANOVA and Tukey's multiple comparisons test. (C) Cardiac output (CO) measured by echocardiography. Data are shown as means ± SEM of $n = 10$ experiments. Horizontal bars indicate significant difference with $P < 0.05$ analyzed by two-way ANOVA and Tukey's multiple comparisons test. (D) Vascular remodeling quantified as degree of muscularization of small (20- to 70- μ m diameter) pulmonary arterial vessels. Vessel muscularization categorized as non, partial, or full after immunostaining against α -smooth muscle actin as marker for PASM and von Willebrand factor to discard endothelium. Data are shown as means ± SEM of $n \geq 4$ experiments. **** $P < 0.0001$ NOX versus HOX analyzed by two-way ANOVA and Tukey's multiple comparisons test. Note, no difference observed between WT versus AOX. (E) Western blots showing HIF-1 α and β -actin expression in WT and AOX transgenic PASM under normoxia and hypoxia. (F) Quantification of protein expression shown in (E). Data are shown as means ± SEM of $n = 3$ experiments. Horizontal bars indicate significant difference with $P < 0.05$ analyzed by two-way ANOVA and Sidak's multiple comparisons test. (G) Proliferation assay of WT and AOX PASM cultured under normoxia (NOX) or hypoxia (HOX, 1% O₂) for 48 hours. Data are shown as means ± SEM of $n = 9$ experiments. Horizontal bars indicate significant difference with $P < 0.05$ analyzed by two-way ANOVA and Tukey's multiple comparisons test. BrdU, bromodeoxyuridine.

pulmonary vascular muscularization (Fig. 4D). Also, we failed to find an advantage of expressing AOX in other cardiac and/or systemic parameters characterizing the response to hypoxia (figs. S3 and S4). HIF-1 α expression was similarly increased in PASM of both strains after 3 days of hypoxia (1% O₂; Fig. 4, E and F), indicating that, at least under these conditions, mitochondrial ROS are not a relevant trigger for HIF-1 α stabilization. By contrast, PASM proliferation was induced by hypoxia in both strains, but its level was generally lower in the presence of AOX (Fig. 4G).

DISCUSSION

Our data substantiate the concept that an increase in superoxide production at cIII is an essential trigger for the HPV signaling cascade, as bypassing cIII during acute hypoxia by AOX inhibits HPV and hypoxia-induced responses in PASM (summarized in Fig. 5). Going beyond, we demonstrate that inhibition of the electron flux distal from the quinone pool and, most likely, at the level of cIV results in electron accumulation at the electron transport chain, which may promote superoxide release from cIII. Restoration of even a small amount of electron flux by bypassing cIII and cIV with AOX is sufficient to prevent HPV. These findings indicate that the mitochondrial respiratory chain can be the primary step in acute hypoxia signaling in the lung, resulting in HPV. Moreover, bypassing the Cox4i2 isoform of cIV as the oxygen-sensitive mitochondrial component at the head of the pathway, which we previously showed to be essential for hypoxia-induced ROS release and mitochondrial hyperpolarization (5), may inhibit hypoxic signaling. Last, our data show that distinct

mechanisms underlie acute and chronic oxygen sensing and signaling in the pulmonary vasculature.

It has been suggested that ROS release from cIII into the intermembrane space could be the essential step in HPV (27, 28). Our previous findings implicating a cIV subunit in hypoxia signaling and cellular membrane depolarization (5) were consistent with this hypothesis, but the initial triggering mechanism of acute hypoxia remained unclear. In the present study, we found that AOX, which is catalytically engaged only when the quinone pool is sufficiently reduced (11), can prevent mitochondrial membrane hyperpolarization, increased superoxide production, and consequent hypoxic signaling. Thus, distal mitochondrial respiratory inhibition and electron flux stalling may act as the initial step in HPV, resulting either in electron accumulation at the quinone pool or the Krebs cycle. As AOX supports electron flux in PASM under low-oxygen conditions that are sufficient to trigger HPV, accumulation of electrons (and thus the hypoxic signaling) is inhibited. A limitation of the current approach using AOX is that one cannot conclude from its effect alone whether the exact source of the excess ROS is cI, cIII, or both. However, we are not aware of any study proposing an increase in ROS formation from cI as a trigger of HPV. Moreover, we cannot exclude that a hypoxia-induced increase or decrease in Krebs cycle intermediates also contributes to the inhibition of hypoxic signaling by AOX. Furthermore, Cox4i2-dependent mitochondrial hyperpolarization may be inhibited as a result of bypassing cIII/cIV. Although the underlying mechanism is not fully elucidated, mitochondrial hyperpolarization may be downstream of ROS, or more distant mechanisms such as glycolytic adenosine triphosphate (ATP) production may contribute to hyperpolarization. Consistent with our study, AOX has previously been shown to decrease mitochondrial ROS production in mouse tissues and cells under various conditions (10, 13, 15, 16). Despite the possibility of multiple trigger mechanisms, the prominent role of hypoxia-induced superoxide release from cIII has been demonstrated previously using the specific cIII inhibitor S3QEL2 (29), which was shown to prevent HPV (5). This finding is now substantiated by our investigation, using AOX. Moreover, knockdown of subunits of cIII was demonstrated to inhibit acute hypoxia-induced responses of the pulmonary vasculature (27).

Hypoxia-dependent PASM membrane depolarization was only partially prevented by AOX, and hypoxia-induced vasoconstriction could be restored by experimentally shifting the cellular membrane potential to higher levels. These findings suggest that multiple sensing mechanisms may contribute to reaching a threshold of cellular membrane depolarization necessary for the final execution of HPV (30). Cellular membrane depolarization might be achieved by a change in cellular redox state or activation of ROS-dependent signaling pathways that influence cell membrane ion channels (1), such as the hydrogen peroxide-mediated inhibition of K_V channels (5). Accordingly, K_V channel inhibition causes cell membrane depolarization and subsequent activation of L- and T-type calcium channels, increasing intracellular calcium levels and triggering HPV (31, 32). The threshold for activation of voltage-dependent calcium channels has been shown to be at a membrane potential between -30 and -20 mV in mouse PASM (33). Thus, while WT PASM can reach this threshold in hypoxia, the presence of AOX prevents membrane depolarization from reaching the critical threshold. The mechanism behind the partial depolarization remains to be identified. A plethora of additional oxygen-sensitive components in PASM have been suggested (1), including hypoxia-sensitive potassium channels (34, 35). Substituting




Fig. 5. Integration of present findings into current concepts of oxygen sensing and HPV in the murine lung. Acute HPV depends on a central oxygen sensor within the mitochondrial respiratory chain. Hypoxia induces mitochondrial membrane hyperpolarization, an increase in mitochondrial superoxide release, and subsequent inhibition of cellular potassium channels (K_V), which leads to cellular membrane depolarization and activation of voltage-gated calcium channels. This sequence of events results in intracellular calcium increase and HPV. AOX prevents HPV in mouse PASM by preventing mitochondrial ROS production and release. This places mitochondria and electron flux through the mitochondrial respiratory chain at the top level in the hierarchy of oxygen sensing and signaling controlling HPV. ADP, adenosine diphosphate; FAD, flavin adenine dinucleotide.

the hypoxic mitochondrial signal by shifting the cellular membrane potential to a critical threshold, as in our experiments by the addition of potassium chloride, may therefore bypass the mitochondrial signaling and thus restore hypoxia-induced cellular membrane depolarization to a level that can trigger calcium increase and HPV. This indicates that mitochondria must be acting far upstream in the signaling hierarchy, and thus, our results demonstrate the essential role of the mitochondrial respiratory chain in acute oxygen sensing and, in addition, provide an explanation for previous, seemingly contradictory, findings with regard to oxygen-sensitive components in PASMCM.

The acute and chronic responses of the pulmonary vasculature to hypoxia have hitherto been assumed to involve similar primary mechanisms and to share regulatory components. However, our data point toward different signaling pathways operating in the two conditions and thus support previous studies that demonstrated a different mechanism of acute HPV and chronic hypoxia-induced PH (5, 30, 36). Confusingly, previous studies have implicated directionally opposite changes in mitochondrial ROS in chronic hypoxia showing both an increase (28) and a decrease in mitochondrial ROS (37) affecting PASMCM proliferation and pulmonary vascular remodeling (38, 39). There are also contradictory reports on the effects of mitochondrial ROS on HIF-1 α , which is a major driver for the development of chronic hypoxia-induced PH (39), with some authors finding evidence of its stabilization by ROS (28, 40), while others found no such effect (41). Recently, we found evidence for a decrease in PASMCM ROS levels in chronic as opposed to acute hypoxia (36). The fact that AOX did not inhibit chronic hypoxia-induced PH, nor interfere with hypoxia-induced stabilization of HIF-1 α , may help resolve these discordant findings, recasting the acute and chronic effects of hypoxia in lungs as two fundamentally different processes. The discrepancy to other studies may be due to cell type-specific mechanisms of HIF-1 α stabilization, or time- and oxygen concentration-dependent differences. For example, nonmitochondrial ROS sources, such as NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidases, may be of greater importance in the pulmonary vasculature under chronic hypoxic conditions. Although under chronic hypoxia AOX did not influence general physiological parameters, we did record a lower proliferation capacity in PASMCM expressing AOX. However, this may be a cell culture effect arising from partial activation of AOX under high glycolytic conditions. It should be emphasized, however, that *in vitro* effects of mitochondrial superoxide release with regard to HIF-1 α stabilization and PASMCM proliferation may differ from the *in vivo* situation.

In summary, our data indicate that respiratory inhibition is an upstream event in HPV signaling, substantiate that mitochondrial superoxide derived from cIII is essential for acute HPV, and provide evidence for the multifactorial nature of HPV with several hypoxia-sensitive components contributing to hypoxia-induced cellular membrane depolarization in PASMCM (Fig. 5). Conversely, oxygen sensing under chronic hypoxia in pulmonary cells operates by distinct mechanisms. The differential effect of AOX on acute and chronic hypoxia in the lung illustrates its value as a tool to study disease etiologies, and eventually opens the possibility of a novel therapeutic approach.

MATERIALS AND METHODS

Reagents and resources

A list of reagents and resources is given in Table 1.

Animal housing and experiments

All animals were maintained and treated according to the regulations of the animal welfare agencies, and all of the experimental protocols were approved by the local “Animal Investigation Care and Use Committee” and the “Regierungspräsidium Darmstadt” (B2/292). Mice and rats were housed in a humidity- and temperature-regulated animal facility with food and water provided *ad libitum*. A general description and characterization of the AOX-expressing strain have been published elsewhere (10). C57BL/6J mice and Sprague-Dawley rats were obtained from Charles River (Sulzfeld, Germany) (Table 1). A list of reagents and resources is given in Table 1 (see below).

Immunohistochemistry

Formalin-fixed paraffin-embedded mouse lung tissue was used for staining with AOX antiserum (1:2000; custom raised in rabbit; 21st Century Biochemicals, Marlborough, MA, USA) (42), visualized using the Zytocem Plus (HRP) Polymer Bulk Kit (Zytomed Systems GmbH, Berlin, Germany) and VECTOR NovaRED Peroxidase (HRP) Substrate Kit (Vector Laboratories, Burlingame, USA).

Hemodynamic measurements in isolated, perfused, and ventilated mouse lungs

Lungs of WT or AOX littermates were isolated, perfused, and ventilated as described elsewhere (30, 43). The AOX inhibitor nPG (Sigma-Aldrich) was titrated to confirm AOX dependence (10 to 20 μ M). The thromboxane analog U46619 (Enzo Life Sciences, Exeter, UK) was used to test the intactness of vasoconstriction (1 ml of bolus with a concentration of 66 ng/ml).

Intrapulmonary artery isolation and tension measurements

Mouse intrapulmonary arteries were isolated and mounted in wire myograph chambers (Danish Myo Technology A/S, Aarhus, Denmark) as described (44). Each experiment was started by 3 \times 3-min exposures to 80 mM KCl containing physiological saline solution. To induce hypoxia upon reaching a stable vascular tone, the N₂-balanced gassing was switched from 21% O₂, 5% CO₂ (Praxair, Danbury, CT, USA) to 1% O₂, 5% CO₂ (Praxair). The partial pressure of O₂ during the hypoxic challenge was 15 to 22 mmHg tested by a FireStingO₂ oxygen meter (PyroScience, Aachen, Germany). Changes in isometric tension from the baseline values were expressed as percentages of the maximum constriction induced by the final exposure to 80 mM KCl. In some experiments, 15 to 20 mM KCl was applied before a hypoxic challenge to achieve precontraction that was ~20% of the maximal constriction induced by 80 mM KCl.

Isolation of mouse and rPASMCM and mouse pulmonary arterial vessels

PASMCM and pulmonary arterial vessels were isolated as described previously (30, 45).

Estimation of the cellular membrane potential

The cellular membrane potential was measured using the patch clamp technique. Mouse PASMCM (passage 0), grown on culture dishes (Greiner Bio-One, Frickenhausen, Germany), were continuously perfused with extracellular analogous bath solution [126.7 mM NaCl (Sigma-Aldrich), 5.4 mM KCl (Carl Roth, Karlsruhe, Germany), 1.8 mM CaCl₂ (Carl Roth), 1.05 mM MgCl₂ (Carl Roth), 0.42 mM NaH₂PO₄ (Merck Millipore, Darmstadt, Germany), 22 mM NaHCO₃ (Carl Roth), 10 mM glucose (Carl Roth), pH7.4]. Bath solution was

Table 1. List of reagents and resources.

Reagents	Source	Identifier
<i>Antibodies</i>		
AOX antiserum (custom raised in rabbit)	21st Century Biochemicals, Marlborough, MA, USA	(42)
HIF-1 α (C-Term) polyclonal antibody	Cayman Chemical	10006421
Anti-beta actin antibody [mAbcam 8226]—loading control (HRP)	Abcam	ab20272
Anti-rabbit IgG (H + L), HRP conjugate	Promega	W4011
Anti-mouse IgG (H + L), HRP conjugate	Promega	W4021
<i>Lentiviral particles</i>		
Lentiviral <i>Ciona intestinalis</i> AOX	This paper	N/A
Lentiviral catalytic inactive (mutant) AOX	This paper	(20)
<i>Chemicals</i>		
n-Propyl gallate (nPG, AOX inhibitor)	Sigma-Aldrich	P3130
U46619 (prostaglandin H2/thromboxane A2 receptor agonist)	Enzo Life Sciences, Exeter, UK	PG-023
Sodium chloride (NaCl)	Sigma-Aldrich	31434
Potassium chloride (KCl)	Carl Roth, Karlsruhe, Germany	5346.1
Calcium chloride (CaCl ₂)	Carl Roth	CN93.1
Magnesium chloride (MgCl ₂)	Carl Roth	KK36.1
Sodium dihydrogen phosphate dihydrate (NaH ₂ PO ₄ ·2H ₂ O)	Merck Millipore, Darmstadt, Germany	1063421000
Sodium hydrogen carbonate (NaHCO ₃)	Carl Roth	8551
D(+)-Glucose	Carl Roth	X997.1
L-Aspartic acid potassium salt (L-aspartate)	Sigma-Aldrich	A6558
Adenosine 5'-triphosphate magnesium salt, ATP	Sigma-Aldrich	A9187
Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA)	Sigma-Aldrich	03777
Hepes (PUFFERAN®)	Carl Roth	9105.3
Potassium hydroxide (KOH)	Carl Roth	6751
1-Hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH spin probe)	Noxygen, Elzach, Germany	NOX-02.2
Superoxide dismutase—polyethylene glycol (pSOD, PEG-SOD)	Sigma-Aldrich	S9549
5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylimidacarbocyanine iodide (JC-1)	ThermoFisher Scientific	T3168
Penicillin-streptomycin	Gibco, ThermoFisher Scientific	1507-063
Normocin—antimicrobial reagent	InvivoGen, San Diego, USA	ant-nr-1
<i>Assays</i>		
ZytoChem Plus (HRP) Polymer Bulk Kit	Zytomed Systems GmbH, Berlin, Germany	POLHRP-100
VECTOR NovaRED Peroxidase (HRP) Substrate Kit	Vector Laboratories, Burlingame, USA	SK-4800
Enhanced chemiluminescence ECL Prime Western Blotting System	GE Healthcare	RPN2232
Cell Proliferation ELISA, BrdU (colorimetric) assay	Sigma-Aldrich	11647229001
<i>Primary cells</i>		
Mouse PASMCM from precapillary pulmonary arterial vessels	(30)	N/A
Rat PASMCM from precapillary pulmonary arterial vessels	(45)	N/A

continued to next page

Reagents	Source	Identifier
<i>Rodent models</i>		
Mouse: Rosa26-Aox (aka Aox ^{Rosa26})	(10)	N/A
Mouse: C57BL/6J	Charles River, Sulzfeld, Germany	Strain Code 632
Rat: Sprague-Dawley (Cri:SD)	Charles River	Strain Code 400
<i>Plasmid and vectors</i>		
pWPXL (constitutive lentiviral plasmid)	Addgene, Boston, MA, USA	Plasmid #12257
pMD2.G (envelope vector)	Addgene	Plasmid #12259
psPAX2 (packing vector)	Addgene	Plasmid #12260
<i>Software and algorithms</i>		
Patchmaster software	HEKA, Lambrecht, Germany	v2x90
IGOR Pro software	Wavemetrics, Lake Oswego, OR, USA	version 6.37
DatLab software	Oroboros Instruments, Innsbruck, Austria	DatLab 5
Prism software	GraphPad Software; San Diego, CA, USA	version 8.2.0
<i>Other</i>		
Multi Wire Myograph System	Danish Myo Technology A/S, Aarhus, Denmark	620 M
N ₂ -balanced gas (21% O ₂ , 5% CO ₂)	Praxair, Danbury, CT, USA	592091 (custom made)
N ₂ -balanced gas (1% O ₂ , 5% CO ₂)	Praxair	650329 (custom made)
Optical Oxygen Meter (FireStingO2)	Pyro Science, Aachen, Germany	FSO2-2
Culture dishes	Greiner Bio-One, Frickenhausen, Germany	627860
Multi-line in-line solution heater	Warner Instruments, Hamden, CT, USA	SHM-8
Borosilicate glass capillary tubes	Sutter Instrument, Novato, CA, USA	BF150-86-10HP
DMZ universal electrode puller	Zeitz, Martinsried, Germany	N/A
EPC 10 USB patch clamp amplifier	HEKA	895000
EMXmicro ESR spectrometer	Bruker Biospin GmbH, Rheinstetten, Germany	N/A
OROBOROS-2k oxygraph	Oroboros Instruments	N/A
Media 199—Mammalian Cell Culture	Gibco, ThermoFisher Scientific	31150-022
Vevo2100 high-resolution imaging system equipped with a 40-MHz transducer	VisualSonics, Toronto, Canada	N/A
Raman spectrometer Shamrock 303i	Andor, Technology, Belfast, UK	SR-303i-A
Laser	Altechna, Vilnius, Lithuania	DPSS 532
Raman filter cube with dichroic mirror	Semrock, Rochester, NY, USA	zt532/640rpc
532-nm EdgeBasic best-value long-pass edge filter	Semrock	BLP01-532R-25
×40 magnification objective	Olympus, Tokyo, Japan	LUCPLFLN

gassed—normoxic (21% O₂, 5.3% CO₂, rest N₂) or hypoxic (1% O₂, 5.3% CO₂, rest N₂)—and preheated to 37°C via an in-line solution heater (Warner Instruments, Hamden, CT, USA). Acute hypoxia was applied by switching from a normoxic to a hypoxic bath solution, and the pO₂ near the cell was recorded by an optical needle-type FireStingO₂ oxygen meter (PyroScience, Aachen, Germany).

Fire-polished patch pipettes with a tip resistance of 3 to 5 megohms were pulled from borosilicate glass capillary tubes (Sutter Instrument, Novato, CA, USA) using a DMZ universal electrode puller (Zeitz, Martinsried, Germany) and filled with intracellular analogous solution containing 105 mM L-aspartate (Sigma-Aldrich), 25 mM KCl (Carl Roth), 4 mM NaCl (Sigma-Aldrich), 1 mM MgCl₂ (Carl Roth), 4 mM ATP (Sigma-Aldrich), 10 mM EGTA (Sigma-Aldrich), and 10 mM Hepes (Carl Roth), pH 7.2 adjusted with 1 M KOH (Carl Roth). Experimentally determined liquid junction potential (+12.3 mV)

was corrected electronically. Cells used for experiments were either relaxed or partially contracted and exhibited spindle-shaped morphology (round and fully contracted cells were discarded). The membrane potential was recorded under current clamp mode ($I = 0$) in whole-cell configuration using an EPC 10 USB patch clamp amplifier (HEKA, Lambrecht, Germany). nPG (Sigma-Aldrich) was added to confirm AOX dependence (10 μM). Data were filtered at 2.9 kHz and sampled at 50 Hz using Patchmaster software (HEKA). Data were analyzed using IGOR Pro software (Wavemetrics, Lake Oswego, OR, USA).

Quantification of superoxide levels by ESR spectroscopy

Intracellular and extracellular ROS concentration was measured using an EMXmicro ESR spectrometer (Bruker Biospin GmbH, Rheinstetten, Germany) using 0.5 mM of the spin probe CMH (Noxygen, Elzach, Germany). The superoxide portion of ROS was determined by

subtracting the ESR signal of the sample with pSOD (Sigma-Aldrich) from the sample incubated for 90 min without pSOD (45 U/ml) in ESR-Krebs Hepes buffer (46, 47). Hypoxia was applied by incubating the cells in a hypoxic chamber (1% O₂ for 5 min).

Lentivirus production and mouse PASMCM transduction

Native or mutated AOX were subcloned into the pWPXL plasmid and packed in a second-generation lentivirus transduction system with pMD2.G as the envelope and psPAX2 as a packing vector (all lentiviral plasmids from Addgene, Boston, MA, USA). Lentiviral transduction was performed with a titer of at least 1×10^7 particles according to established protocols (see <http://tronolab.epfl.ch/> for more details). After 3 days of transduction, PASMCM were used for further experiments.

Measuring mitochondrial membrane potential

The mitochondrial membrane potential was studied by fluorescence microscopy using 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylimidocarbocyanine iodide (JC-1) as recommended by the manufacturer (Thermo Fisher Scientific, Waltham, MA, USA). Acute hypoxia was induced by switching from a normoxic perfusion buffer to a hypoxic buffer (1% O₂).

High-resolution respirometry

Oxygen consumption was determined at 37°C using an OROBOROS-2 k oxygraph (Oroboros Instruments, Innsbruck, Austria) as described previously (5). Briefly, primary rPASMCM were trypsinized, washed two times, and resuspended in M199 medium (Gibco, Thermo Fisher Scientific, Hampton, NH, USA) containing 1% penicillin-streptomycin (Gibco, Thermo Fisher Scientific) and 10% Hepes (Carl Roth). PASMCM transfected with an empty or AOX-containing vector were measured in parallel. Oxygen consumption was recorded continuously until the oxygen was depleted. DatLab software (Oroboros Instruments) was used to calculate oxygen consumption as the time derivative of the oxygen content, standardized to cell number.

Raman spectroscopy on PASMCM

Raman spectra of mouse WT and AOX PASMCM were measured using a home-built microscope equipped with a $\times 40$ magnification microscope objective (Olympus, Tokyo, Japan), a Raman spectrometer (Andor Technology, Belfast, UK), and a laser with an excitation wavelength of 532 nm (Altechna, Vilnius, Lithuania). The Raman signal was filtered out from the laser light using a filter cube containing a dichroic mirror (Semrock, Rochester, NY, USA) and a 532-nm edge filter (Semrock). An in-house-designed gas-tight microfluidic system was used to register Raman spectra on the cultured PASMCM at different oxidation states, i.e., normoxic and hypoxic conditions (48). The sample was illuminated with a laser output power of 3.1 mW with an integration time of 60 s. Acquired Raman data were processed in two steps. First, Cosmic rays were removed using the 2D second difference (49). Second, an optimal reconstruction was done using a Savitzky-Golay filter (50). To confirm the Raman signal from the single live cells, background spectra of the microfluidic system and the buffer were taken.

Right ventricular hemodynamics and morphometry and vascular remodeling

Mice were exposed to normobaric hypoxia (10% O₂) for 4 weeks. Quantification of PH was performed as described (30). Measurement

of transthoracic echocardiography was performed in the mice before measurement of invasive hemodynamics using a Vevo2100 high-resolution imaging system equipped with a 40-MHz transducer (VisualSonics, Toronto, Canada) as described previously (5, 36).

Western blot analysis

Hypoxic exposure of PASMCM, protein extraction, and Western blot analysis were performed as described (5). Primary antibodies used were anti-HIF-1 α (1:1000 dilution; Cayman Chemical) and anti- β -actin (1:50,000 dilution; Abcam). Specific immune-reactive signals were detected using enhanced chemiluminescence ECL Prime Western Blotting System (GE Healthcare) using a proprietary secondary antibody coupled to horseradish peroxidase (1:5000 dilution; Promega).

Bromodeoxyuridine proliferation assay

For assessment of proliferation, mouse PASMCM (5000 cells per well) from passage 1 were seeded in 24-well plates in smooth muscle cell basal medium containing 1% normocin (InvivoGen, San Diego, USA). After 24 hours of starvation, cells were exposed to normoxia (21% O₂, 5% CO₂) or hypoxia (1% O₂, 5% CO₂) at 37°C in water-saturated incubators for 72 hours. Bromodeoxyuridine (BrdU) labeling reagent was added 18 hours before the end of the incubation period. The proliferation assay was performed according to the manufacturer's instructions [Cell Proliferation ELISA, BrdU (colorimetric), Sigma-Aldrich]. The absorbance of the substrate reaction was measured after 15 min of incubation at 370 nm (reference wavelength, 492 nm).

Statistical analysis

All data depicted are shown as means \pm SEM. The exact group size is stated in each figure legend. If not stated otherwise, statistical analysis was done using Prism (GraphPad Software). Differences were considered statistically significant at a *P* value <0.05.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <http://advances.sciencemag.org/cgi/content/full/6/16/eaba0694/DC1>

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

1. N. Sommer, I. Strielkov, O. Pak, N. Weissmann, Oxygen sensing and signal transduction in hypoxic pulmonary vasoconstriction. *Eur. Respir. J.* **47**, 288–303 (2016).
2. J. T. Sylvester, L. A. Shimoda, P. I. Aaronson, J. P. T. Ward, Hypoxic pulmonary vasoconstriction. *Physiol. Rev.* **92**, 367–520 (2012).
3. B. Mathew, S. Lakshminrusimha, Persistent pulmonary hypertension in the newborn. *Children* **4**, 63 (2017).
4. J. Grimmering, M. Richter, K. Tello, N. Sommer, H. Gall, H. A. Ghofrani, Thin air resulting in high pressure: Mountain sickness and hypoxia-induced pulmonary hypertension. *Can. Respir. J.* **2017**, 8381653 (2017).
5. N. Sommer, M. Hüttemann, O. Pak, S. Scheibe, F. Knoepp, C. Sinkler, M. Malczyk, M. Gierhardt, A. Esfandiary, S. Kraut, F. Jonas, C. Veith, S. Aras, A. Sydykov, N. Alebrahimdehkordi, K. Giehl, M. Hecker, R. P. Brandes, W. Seeger, F. Grimmering, H. A. Ghofrani, R. T. Schermuly, L. I. Grossman, N. Weissmann, Mitochondrial complex IV subunit 4 isoform 2 is essential for acute pulmonary oxygen sensing. *Circ. Res.* **121**, 424–438 (2017).
6. O. Pak, N. Sommer, T. Hoeres, A. Bakr, S. Waisbrod, A. Sydykov, D. Haag, A. Esfandiary, B. Kojonazarov, F. Veit, B. Fuchs, F. C. Weisel, M. Hecker, R. T. Schermuly, F. Grimmering, H. A. Ghofrani, W. Seeger, N. Weissmann, Mitochondrial hyperpolarization in pulmonary vascular remodeling. Mitochondrial uncoupling protein deficiency as disease model. *Am. J. Respir. Cell Mol. Biol.* **49**, 358–367 (2013).
7. M. Mittal, X. Q. Gu, O. Pak, M. E. Pamerter, D. Haag, D. B. Fuchs, R. T. Schermuly, H. A. Ghofrani, R. P. Brandes, W. Seeger, F. Grimmering, G. G. Haddad, N. Weissmann, Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. *Free Radic. Biol. Med.* **52**, 1033–1042 (2012).

8. K. J. Dunham-Snary, D. Wu, F. Potus, E. A. Sykes, J. D. Mewburn, R. L. Charles, P. Eaton, R. A. Sultanian, S. L. Archer, Ndufs2, a core subunit of mitochondrial complex I, is essential for acute oxygen-sensing and hypoxic pulmonary vasoconstriction. *Circ. Res.* **124**, 1727–1746 (2019).
9. G. B. Waypa, K. A. Smith, P. T. Schumacker, O₂ sensing, mitochondria and ROS signaling: The fog is lifting. *Mol. Aspects Med.* **47–48**, 76–89 (2016).
10. M. Szibor, P. K. Dhandapani, E. Dufour, K. M. Holmström, Y. Zhuang, I. Salwig, I. Wittig, J. Heidler, Z. Gizatullina, T. Gainutdinov; German Mouse Clinic Consortium, H. Fuchs, V. Gailus-Durner, M. H. de Angelis, J. Nandania, V. Velagapudi, A. Wietelmann, P. Rustin, F. N. Gellerich, H. T. Jacobs, T. Braun, Broad AOX expression in a genetically tractable mouse model does not disturb normal physiology. *Dis. Model. Mech.* **10**, 163–171 (2017).
11. I. B. Dry, A. L. Moore, D. A. Day, J. T. Wiskich, Regulation of alternative pathway activity in plant mitochondria: Nonlinear relationship between electron flux and the redox poise of the quinone pool. *Arch. Biochem. Biophys.* **273**, 148–157 (1989).
12. E. L. Robb, A. R. Hall, T. A. Prime, S. Eaton, M. Szibor, C. Viscomi, A. M. James, M. P. Murphy, Control of mitochondrial superoxide production by reverse electron transport at complex I. *J. Biol. Chem.* **293**, 9869–9879 (2018).
13. R. El-Khoury, E. Dufour, M. Rak, N. Ramanantsoa, N. Grandchamp, Z. Csaba, B. Duvallié, P. Bénéit, J. Gallego, P. Gressens, C. Sarkis, H. T. Jacobs, P. Rustin, Alternative oxidase expression in the mouse enables bypassing cytochrome c oxidase blockade and limits mitochondrial ROS overproduction. *PLoS Genet.* **9**, e1003182 (2013).
14. M. Szibor, T. Gainutdinov, E. Fernández-Vizarrá, E. Dufour, Z. Gizatullina, G. Debska-Vielhaber, J. Heidler, I. Wittig, C. Viscomi, F. Gellerich, A. L. Moore, Bioenergetic consequences from xenotopic expression of a tunicate AOX in mouse mitochondria: Switch from RET and ROS to FET. *Biochim. Biophys. Acta Bioenerg.* **1861**, 148137 (2019).
15. E. L. Mills, B. Kelly, A. Logan, A. S. H. Costa, M. Varma, C. E. Bryant, P. Tourlomos, J. H. M. Däbritz, E. Gottlieb, I. Latorre, S. C. Corr, G. McManus, D. Ryan, H. T. Jacobs, M. Szibor, R. J. Xavier, T. Braun, C. Frezza, M. P. Murphy, L. A. O'Neill, Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. *Cell* **167**, 457–470.e13 (2016).
16. L. Giordano, A. Farnham, P. K. Dhandapani, L. Salminen, J. Bhaskaran, R. Voswinckel, P. Rauschkolb, S. Scheibe, N. Sommer, C. Beisswenger, N. Weissmann, T. Braun, H. T. Jacobs, R. Bals, C. Herr, M. Szibor, Alternative oxidase attenuates cigarette smoke-induced lung dysfunction and tissue damage. *Am. J. Respir. Cell Mol. Biol.* **60**, 515–522 (2019).
17. R. El-Khoury, K. K. Kempainen, E. Dufour, M. Szibor, H. T. Jacobs, P. Rustin, Engineering the alternative oxidase gene to better understand and counteract mitochondrial defects: State of the art and perspectives. *Br. J. Pharmacol.* **171**, 2243–2249 (2014).
18. E. P. Dassa, E. Dufour, S. Goncalves, H. T. Jacobs, P. Rustin, The alternative oxidase, a tool for compensating cytochrome c oxidase deficiency in human cells. *Physiol. Plant.* **137**, 427–434 (2009).
19. P. Rustin, H. T. Jacobs, Respiratory chain alternative enzymes as tools to better understand and counteract respiratory chain deficiencies in human cells and animals. *Physiol. Plant.* **137**, 362–370 (2009).
20. A. Andjelković, M. T. Oliveira, G. Cannino, C. Yalgin, P. K. Dhandapani, E. Dufour, P. Rustin, M. Szibor, H. T. Jacobs, Diiron centre mutations in ciona intestinalis alternative oxidase abolish enzymatic activity and prevent rescue of cytochrome oxidase deficiency in flies. *Sci. Rep.* **5**, 18295 (2015).
21. N. A. Brazhe, M. Treiman, B. Faricelli, J. H. Vestergaard, O. Sosnovtseva, In situ Raman study of redox state changes of mitochondrial cytochromes in a perfused rat heart. *PLoS ONE* **8**, e70488 (2013).
22. H. Teng, M. Lv, L. Liu, X. Zhang, Y. Zhao, Z. Wu, H. Xu, Quantitative detection of NADH using a novel enzyme-assisted method based on surface-enhanced Raman scattering. *Sensors* **17**, E788 (2017).
23. T. G. Spiro, T. C. Streaks, Resonance Raman spectra of hemoglobin and cytochrome c: Inverse polarization and vibronic scattering. *Proc. Natl. Acad. Sci. U.S.A.* **69**, 2622–2626 (1972).
24. N. Erjavec, G. Pinato, K. Ramser, Raman spectroscopy as a tool for detecting mitochondrial fitness. *J. Raman Spectrosc.* **47**, 933–939 (2016).
25. S. Choi, J. J. Lee, Y. H. Wei, T. G. Spiro, Resonance Raman and electronic spectra of heme a complexes and cytochrome oxidase. *J. Am. Chem. Soc.* **105**, 3692–3707 (1983).
26. J. D. Marshall, I. Bazan, Y. Zhang, W. H. Fares, P. J. Lee, Mitochondrial dysfunction and pulmonary hypertension: Cause, effect, or both. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **314**, L782–L796 (2018).
27. G. B. Waypa, J. D. Marks, R. D. Guzy, P. T. Mungai, J. M. Schriewer, D. Dokic, M. K. Ball, P. T. Schumacker, Superoxide generated at mitochondrial complex III triggers acute responses to hypoxia in the pulmonary circulation. *Am. J. Respir. Crit. Care Med.* **187**, 424–432 (2013).
28. P. T. Schumacker, Lung cell hypoxia: Role of mitochondrial reactive oxygen species signaling in triggering responses. *Proc. Am. Thorac. Soc.* **8**, 477–484 (2011).
29. A. L. Orr, L. Vargas, C. N. Turk, J. E. Baaten, J. T. Matzen, V. J. Dardov, S. J. Attle, J. Li, D. C. Quackenbush, R. L. S. Goncalves, I. V. Perevoshchikova, H. M. Petrassi, S. L. Meeusen, E. K. Ainscow, M. D. Brand, Suppressors of superoxide production from mitochondrial complex III. *Nat. Chem. Biol.* **11**, 834–836 (2015).
30. N. Weissmann, A. Dietrich, B. Fuchs, H. Kalwa, M. Ay, R. Dumitrascu, A. Olschewski, U. Storch, M. Mederos y Schnitzler, H. A. Ghofrani, R. T. Schermuly, O. Pinkenburg, W. Seeger, F. Grimminger, T. Gudermann, Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 19093–19098 (2006).
31. F. Veit, O. Pak, R. P. Brandes, N. Weissmann, Hypoxia-dependent reactive oxygen species signaling in the pulmonary circulation: Focus on ion channels. *Antioxid. Redox Signal.* **22**, 537–552 (2015).
32. A. L. Firth, C. V. Remillard, O. Platoshyon, I. Fantozzi, E. A. Ko, J. X.-J. Yuan, Functional ion channels in human pulmonary artery smooth muscle cells: Voltage-dependent cation channels. *Pulm. Circ.* **1**, 48–71 (2011).
33. E. A. Ko, J. Wan, A. Yamamura, A. M. Zimnicka, H. Yamamura, H. Y. Yoo, H. Tang, K. A. Smith, P. C. Sundivakkam, A. Zeifman, R. J. Ayon, A. Makino, J. X.-J. Yuan, Functional characterization of voltage-dependent Ca²⁺ channels in mouse pulmonary arterial smooth muscle cells: Divergent effect of ROS. *Am. J. Physiol. Cell Physiol.* **304**, C1042–C1052 (2013).
34. A. Olschewski, E. L. Veale, B. M. Nagy, C. Nagaraj, G. Kwapiszewska, F. Antigny, M. Lambert, M. Humbert, G. Cziráj, P. Enyedi, A. Mathie, TASK-1 (KCNK3) channels in the lung: From cell biology to clinical implications. *Eur. Respir. J.* **50**, 1700754 (2017).
35. E. K. Weir, A. Olschewski, Role of ion channels in acute and chronic responses of the pulmonary vasculature to hypoxia. *Cardiovasc. Res.* **71**, 630–641 (2006).
36. O. Pak, S. Scheibe, A. Esfandiary, M. Gierhardt, A. Sydykov, A. Logan, A. Fysikopoulos, F. Veit, M. Hecker, F. Kroschel, K. Quanz, A. Erb, K. Schäfer, M. Fassbinder, N. Alebrahimdehordi, H. A. Ghofrani, R. T. Schermuly, R. P. Brandes, W. Seeger, M. P. Murphy, N. Weissmann, N. Sommer, Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension. *Eur. Respir. J.* **51**, 1701024 (2018).
37. P. Dromparis, G. Sutendra, E. D. Michelakis, The role of mitochondria in pulmonary vascular remodeling. *J. Mol. Med.* **88**, 1003–1010 (2010).
38. S. E. Adesina, B.-Y. Kang, K. M. Bijli, J. Ma, J. Cheng, T. C. Murphy, C. Michael Hart, R. L. Sutliff, Targeting mitochondrial reactive oxygen species to modulate hypoxia-induced pulmonary hypertension. *Free Radic. Biol. Med.* **87**, 36–47 (2015).
39. M. K. Ball, G. B. Waypa, P. T. Mungai, J. M. Nielsen, L. Czech, V. J. Dudley, L. Beussink, R. W. Dettman, S. K. Berkelhamer, R. H. Steinhorn, S. J. Shah, P. T. Schumacker, Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1 α . *Am. J. Respir. Crit. Care Med.* **189**, 314–324 (2014).
40. I. Martínez-Reyes, L. P. Diebold, H. Kong, M. Schieber, H. Huang, C. T. Hensley, M. M. Mehta, T. Wang, J. H. Santos, R. Woychik, E. Dufour, J. N. Spellbrink, S. E. Weinberg, Y. Zhao, R. J. DeBerardinis, N. S. Chandel, TCA cycle and mitochondrial membrane potential are necessary for diverse biological functions. *Mol. Cell* **61**, 199–209 (2016).
41. Y. L. Chua, E. Dufour, E. P. Dassa, P. Rustin, H. T. Jacobs, C. T. Taylor, T. Hagen, Stabilization of hypoxia-inducible factor-1 α protein in hypoxia occurs independently of mitochondrial reactive oxygen species production. *J. Biol. Chem.* **285**, 31277–31284 (2010).
42. E. P. Dassa, E. Dufour, S. Gonçalves, V. Paupe, G. A. J. Hakkaart, H. T. Jacobs, P. Rustin, Expression of the alternative oxidase complements cytochrome c oxidase deficiency in human cells. *EMBO Mol. Med.* **1**, 30–36 (2009).
43. N. Weissmann, A. Sydykov, H. Kalwa, U. Storch, B. Fuchs, M. Mederos y Schnitzler, R. P. Brandes, F. Grimminger, M. Meissner, M. Freichel, S. Offermanns, F. Veit, O. Pak, K.-H. Krause, R. T. Schermuly, A. C. Brewer, H. H. W. Schmidt, W. Seeger, A. M. Shah, T. Gudermann, H. A. Ghofrani, A. Dietrich, Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. *Nat. Commun.* **3**, 649 (2012).
44. I. Strielkov, N. C. Krause, N. Sommer, R. T. Schermuly, H. A. Ghofrani, F. Grimminger, T. Gudermann, A. Dietrich, N. Weissmann, Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels. *Exp. Physiol.* **103**, 1185–1191 (2018).
45. F. Veit, O. Pak, B. Egemnazarov, M. Roth, D. Kosanovic, M. Seimetz, N. Sommer, H. A. Ghofrani, W. Seeger, F. Grimminger, R. P. Brandes, R. T. Schermuly, N. Weissmann, Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. *Antioxid. Redox Signal.* **19**, 2213–2231 (2013).
46. N. Weissmann, N. Kuzkaya, B. Fuchs, V. Tiyerili, R. U. Schäfer, H. Schütte, H. A. Ghofrani, R. T. Schermuly, C. Schudt, A. Sydykov, B. Egemnazarov, W. Seeger, F. Grimminger, Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. *Respir. Res.* **6**, 86 (2005).
47. S. I. Dikalov, W. Li, P. Mehranpour, S. S. Wang, A. M. Zafari, Production of extracellular superoxide by human lymphoblast cell lines: Comparison of electron spin resonance techniques and cytochrome C reduction assay. *Biochem. Pharmacol.* **73**, 972–980 (2007).
48. F. Knoepf, J. Wahl, A. Andersson, J. Borg, N. Weissmann, K. Ramser, Development of a gas-tight microfluidic system for Raman sensing of single pulmonary arterial smooth muscle cells under Normoxic/Hypoxic conditions. *Sensors* **18**, E3238 (2018).
49. H. G. Schulze, R. F. B. Turner, A two-dimensionally coincident second difference cosmic ray spike removal method for the fully automated processing of Raman spectra. *Appl. Spectrosc.* **68**, 185–191 (2014).

50. A. Savitzky, M. J. E. Golay, Smoothing and differentiation of data by simplified least squares procedures. *Anal. Chem.* **36**, 1627–1639 (1964).

Acknowledgments: We thank K. Homberger, E. Kappes, I. Breitenborn-Mueller, and M. Partanen for technical assistance. **Funding:** This work was supported by the European Research Council (Advanced Grant 232738), Academy of Finland (Centre of Excellence grant 272376 and Academy Professorship grant 256615), Tampere University Hospital Medical Research Fund and Sigrid Juselius Foundation (to H.T.J.), the Swedish Research Council (grant 2016-04220 to K.R.), and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, project no. 268555672, SFB 1213, A06 to N.W. and N.S.). **Author contributions:** All authors performed research or compiled and analyzed data. N.S., N.W., H.T.J., and M.S. designed and supervised the research and drafted the manuscript, which was then finalized by all authors. **Competing interests:** H.T.J. is an inventor on a PATENT related to this work filed by Inst Nat Sante Rech Med (no. 7572616, published 10/09/2008). M.S. declares himself a shareholder in a startup company to develop AOX therapeutics. All other authors declare that they have no competing interests. **Data and materials availability:** All data needed to

evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The mice xenotopically expressing *Ciona intestinalis* alternative oxidase (AOX) can be provided by the Faculty of Medicine and Health Technology, Tampere University, FI-33520 Tampere, Finland, pending scientific review and a completed material transfer agreement. Requests for the mice should be submitted to Prof. Howard T. Jacobs (howard.jacobs@tuni.fi).

Submitted 1 November 2019

Accepted 22 January 2020

Published 15 April 2020

10.1126/sciadv.aba0694

Citation: N. Sommer, N. Alebrahimdehordi, O. Pak, F. Knoepp, I. Strielkov, S. Scheibe, E. Dufour, A. Andjelković, A. Sydykov, A. Saraji, A. Petrovic, K. Quanz, M. Hecker, M. Kumar, J. Wahl, S. Kraut, W. Seeger, R. T. Schermuly, H. A. Ghofrani, K. Ramser, T. Braun, H. T. Jacobs, N. Weissmann, M. Szibor, Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. *Sci. Adv.* **6**, eaba0694 (2020).

Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing

Natascha Sommer, Nasim Alebrahimdehordi, Oleg Pak, Fenja Knoepp, Ievgen Strielkov, Susan Scheibe, Eric Dufour, Ana Andjelkovic, Akylbek Sydykov, Alireza Saraji, Aleksandar Petrovic, Karin Quanz, Matthias Hecker, Manish Kumar, Joel Wahl, Simone Kraut, Werner Seeger, Ralph T. Schermuly, Hossein A. Ghofrani, Kerstin Ramser, Thomas Braun, Howard T. Jacobs, Norbert Weissmann and Marten Szibor

Sci Adv 6 (16), eaba0694.
DOI: 10.1126/sciadv.aba0694

ARTICLE TOOLS

<http://advances.sciencemag.org/content/6/16/eaba0694>

SUPPLEMENTARY MATERIALS

<http://advances.sciencemag.org/content/suppl/2020/04/13/6.16.eaba0694.DC1>

REFERENCES

This article cites 50 articles, 10 of which you can access for free
<http://advances.sciencemag.org/content/6/16/eaba0694#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

Science Advances (ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Advances* is a registered trademark of AAAS.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).